Compare ENOV & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | ANIP |
|---|---|---|
| Founded | 1995 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2008 | 1999 |
| Metric | ENOV | ANIP |
|---|---|---|
| Price | $23.45 | $74.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $48.75 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 1.0M | 333.7K |
| Earning Date | 06-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $6.49 | $19.88 |
| Revenue Next Year | $5.56 | $15.77 |
| P/E Ratio | ★ N/A | $22.32 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $21.00 | $56.71 |
| 52 Week High | $40.70 | $99.50 |
| Indicator | ENOV | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 46.55 |
| Support Level | $21.30 | $74.28 |
| Resistance Level | $23.57 | $85.12 |
| Average True Range (ATR) | 1.21 | 2.87 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 17.91 | 57.96 |
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.